Trial reportDiabetes care2010
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 69 citations in OpenAlex.
- Effect of atorvastatin on testosterone levels.The Cochrane database of systematic reviews · 2021Pooled it
- Fibrates for primary prevention of cardiovascular disease events.The Cochrane database of systematic reviews · 2016 · on this mapPooled it
- Lipid-lowering efficacy of atorvastatin.The Cochrane database of systematic reviews · 2015 · on this mapPooled it
- High-dose atorvastatin improves vascular endothelial function in patients with leukoaraiosis.Journal of clinical laboratory analysis · 2020Trial
- The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.European journal of clinical pharmacology · 2011Trial
- Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.Journal of cellular and molecular medicine · 2025Review
- Association of Fibrate use with clinical expression of hypertrophic cardiomyopathy.ESC heart failure · 2024Article
- The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.Metabolites · 2024Review
- Anti-inflammatory role of fenofibrate in treating diseases.Biomolecules & biomedicine · 2023Review
- Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction.Diabetes & metabolism journal · 2020Review
- Distinct but complementary contributions of PPAR isotypes to energy homeostasis.The Journal of clinical investigation · 2017Review
- The production of coagulation factor VII by adipocytes is enhanced by tumor necrosis factor-α or isoproterenol.International journal of obesity (2005) · 2015Article
- Treatment and impact of dyslipidemia in diabetic nephropathy.Clinical and experimental nephrology · 2014Review
- Effect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemia.World journal of diabetes · 2013Article
- PAI-1 and diabetes: a journey from the bench to the bedside.Diabetes care · 2012Article
- Metabolic syndrome in the Mediterranean region: Current status.Indian journal of endocrinology and metabolism · 2012Article
- Metabolic syndrome and neurotrophins: effects of metformin and non-steroidal antiinflammatory drug treatment.The Eurasian journal of medicine · 2011Article
- Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.Archives of medical science : AMS · 2011Article
- Review
- Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare extra-lipid effects of statins and fibrates in relation to the baseline metabolic status of patients. RESEARCH DESIGN AND
methodsThe study involved a group of 242 metabolic syndrome patients with or without pre-diabetes and randomized to atorvastatin, fenofibrate, or placebo.
resultsCompared with matched healthy subjects, metabolic syndrome patients exhibited higher plasma levels/activities of high-sensitivity C-reactive protein (hs-CRP), fibrinogen, factor VII, plasminogen activator inhibitor 1, and enhanced monocyte cytokine release. These abnormalities were alleviated by both atorvastatin and fenofibrate treatment. CRP-lowering and monocyte-suppressing actions were more pronounced for atorvastatin in subjects with impaired fasting glucose and for fenofibrate in patients with impaired glucose tolerance.
conclusionsThe presence of pre-diabetes potentiates metabolic syndrome-induced abnormalities in plasma markers of inflammation and hemostasis and in monocyte secretory function. Both atorvastatin and fenofibrate exhibit multidirectional pleiotropic effects in subjects with metabolic syndrome, the strength of which seem to be partially determined by the type of pre-diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.